The presence of mutations within DDR1 kinase domain in multiple cancers, such as non‐small cell lung cancer (Ford et al., 2007) and acute myeloid leukemia (Tomasson et al., 2008), which may result in the resistance to small molecular inhibitors, has been reported. This evidence concerns the gene DDR1 and lung cancer.